Biotech · Public company · South San Francisco, CA, US
Sutro Biopharma, Inc.
Ticker STRO · SEC CIK 0001382101
Track this companyFree. Adds Sutro Biopharma, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials82 recruiting or active
Pipeline programs15From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline15
- GemcitabinePhase 3 · Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- Luveltamab tazevibulinPhase 3 · Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- PaclitaxelPhase 3 · Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- PegfilgrastimPhase 3 · Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- Pegylated liposomal doxorubicinPhase 3 · Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- TopotecanPhase 3 · Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- Luveltamab tazevibulinPhase 2 · Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- Luveltamab tazevibulinPhase 2 · Acute Myeloid Leukemia (AML)ClinicalTrials.gov · fetched Nov 12, 2026
- BevacizumabPhase 1 · Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 1 · Head & Neck Squamous Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 1 · Head and Neck Squamous Cell Carcinoma HNSCCClinicalTrials.gov · fetched Nov 12, 2026
- STRO-001Phase 1 · B-cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- STRO-002Phase 1 · Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- STRO-004Phase 1 · Head and Neck Squamous Cell Carcinoma HNSCCClinicalTrials.gov · fetched Nov 12, 2026
- STRO-006Phase 1 · Head & Neck Squamous Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials8
- Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or MetastaticPHASE1 · RECRUITING · started Oct 19, 2026ClinicalTrials.gov NCT07807345 · fetched Nov 12, 2026
- A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic CancerPHASE1 · RECRUITING · started Nov 7, 2025ClinicalTrials.gov NCT07227168 · fetched Nov 12, 2026
- Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AMLPHASE1_PHASE2 · TERMINATED · started Dec 4, 2024ClinicalTrials.gov NCT06679582 · fetched Nov 12, 2026
- Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung CancerPHASE2 · WITHDRAWN · started Aug 21, 2024ClinicalTrials.gov NCT06555263 · fetched Nov 12, 2026
- REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1PHASE2_PHASE3 · TERMINATED · started Jul 12, 2023ClinicalTrials.gov NCT05870748 · fetched Nov 12, 2026
- A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian CancerPHASE1 · TERMINATED · started Mar 22, 2022ClinicalTrials.gov NCT05200364 · fetched Nov 12, 2026
- Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial CancersPHASE1 · COMPLETED · started Feb 1, 2019ClinicalTrials.gov NCT03748186 · fetched Nov 12, 2026
- Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell MalignanciesPHASE1 · COMPLETED · started Feb 22, 2018ClinicalTrials.gov NCT03424603 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Aug 12, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 12, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 8, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 14, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 14, 2026 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Mar 23, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 23, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Feb 10, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Dec 17, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Dec 3, 2025 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Nov 6, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 6, 2025 · fetched Nov 12, 2026